Meeting
2019 Gastrointestinal Cancers Symposium
A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer.
Authors
Christine Campo Alewine
Center for Cancer Research, NCI, NIH, Bethesda, MD
Christine Campo Alewine , Raffit Hassan , M. Iqra Ahmad , Jane B Trepel , Cody Peer , William Douglas Figg , Ira Pastan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02810418
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 307)
DOI
10.1200/JCO.2019.37.4_suppl.307
Abstract #
307
Poster Bd #
G5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc).
First Author: John Davelaar
Poster
2017 ASCO Annual Meeting
Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.
First Author: Kian-Huat Lim
Poster
2016 Gastrointestinal Cancers Symposium
A phase I trial of cabozantinib (XL184) and gemcitabine in advanced pancreatic cancer.
First Author: David Bing Zhen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase I study of trifluridine/tipiracil in combination with gemcitabine (gem) and nab-paclitaxel (nab-P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Anita Ahmed Turk